Company Information
CIN
Status
Date of Incorporation
16 March 1979
State / ROC
Uttarakhand / ROC Uttarakhand
Last Balance Sheet
31 March 2023
Last Annual Meeting
29 September 2023
Paid Up Capital
74,546,150
Authorised Capital
100,000,000
Directors
Harish Pande
Director/Designated Partner
about 2 years ago
about 2 years ago
Ashwani Kumar Sharma
Director/Designated Partner
over 2 years ago
over 2 years ago
Ravi Kumar Bansal
Director/Designated Partner
about 6 years ago
about 6 years ago
Sangeeta Bishnoi
Director/Designated Partner
about 6 years ago
about 6 years ago
Sumita Dwivedi
Director/Designated Partner
about 6 years ago
about 6 years ago
Vimal Kumar Shrawat
Director/Designated Partner
about 7 years ago
about 7 years ago
Suresh Kumar Singh
Director/Designated Partner
about 7 years ago
about 7 years ago
Sanjay Bansal
Director/Designated Partner
about 7 years ago
about 7 years ago
Arun Kumar
Director/Designated Partner
about 10 years ago
about 10 years ago
Kailash Gupta
Director/Designated Partner
about 11 years ago
about 11 years ago
Rahul Bishnoi
Director/Designated Partner
almost 24 years ago
almost 24 years ago
Past Directors
Akshay Kant Chaturvedi
Additional Director
over 7 years ago
over 7 years ago
Usha Pande
Director
about 10 years ago
about 10 years ago
Anirudh Bishnoi
Whole Time Director
over 18 years ago
over 18 years ago
Puneet Chandra
Director
about 19 years ago
about 19 years ago
Tejasvi Bishnoi
Director
over 22 years ago
over 22 years ago
Patents
The present invention provides process for preparation of highly pure Fingolimod hydrochloride (I) having purity of greater than 99.8% (by HPLC),
(I)
without involving the use of column chromatographic purification in the entire process. Fingolimod hydrochloride (I) obtained by the process of present invention ma...
The present invention relates to an environment friendly and direct one pot process for preparing highly pure Monomethyl Fumarate (I)
without involving any isolation of any intermediates.
The improved process of present invention is industrially upscalable and provides highly pure 4-methoxy-4-oxobut-2-enoic acid...
The present invention provides to an improved process for the preparation
of highly pure Erlotinib hydrochloride of formula (I)
The substantially pure Erlotinib hydrochloride (I) obtained by improved
process of the present invention is having purity of greater than 99.8% (by HPLC).
Erlotinib hydrochloride is use...
The invention relates to pharmaceutical composition comprising 86.0-96.0 % w/w of Imatinib mesylate, 0.05-0.2% w/w of binder and 1-6% w/w of disintegrant, wherein the composition is prepared using binder in isopropyl alcohol solvent. Said pharmaceutical compositions comprising Imatinib mesylate provides improved sta...
The invention relates to stable oral pharmaceutical composition comprising 3-8% w/v of magnesium hydroxide, 15-40% v/v of liquid paraffin and 0.01-1.0% w/v of sodium picosulfate, 01-05% w/v of colloidal anhydrous silica as stabilizing agent and 1-4% w/v of non-ionic surfactant, wherein the composition is prepared us...
The present invention provides a commercially viable process for preparation of highly pure Temozolomide (VI), which is useful in the treatment of cancer. The invention also provides an economically viable process for an intermediate compound of formula III useful in the process for preparing Temozolomide.
...
A pharmaceutical composition of Otilonium bromide comprising of an immediate release layer and sustained release layer which may be used for the treatment of irritable bowel syndrome or spasmodic pain of the gut.
The invention provides a prolonged release pharmaceutical composition of
Indapamide comprising 0.1-2%) w/w of Indapamide, 10-25%) w/w of one or more
cellulose derivatives polymers with the viscosity of 20-80 cP measured using 0.5%
w/w of aqueous solution. The prolonged release pharmaceutical composition of
Indap...
A commercially viable process for the preparation of 2-amino
cyanoacetamide of formula (I)
(I)
which is a useful pharmaceutical intermediate for preparing Temozolomide API
useful in the treatment of cancer.
The process according to the present invention results in highly pure
material, which is desirable to pr...
The present invention relates to a process for the preparation of the active pharmaceutical ingredient Fingolimod Hydrochloride (I) and its highly pure intermediate [2-acetamido-2-(acetyloxy methyl)-4-phenylbutyl] acetate(II)
(I) (II)
The present invention relates to a process for preparation of crystalline Ambroxol Hydrochloride (I)
(I)
The present invention further relates to a process for preparation of Crystalline Form-SAH of Ambroxol Hydrochloride.
NITROSAMINE IMPURITIES
ABSTRACT
The present invention relates to a new, robust, economical and industrially viable Reverse Phase-High performance liquid chromatography (RP-HPLC) method for the determination and quantification of genotoxic nitrosamine impurities in drug substance or drug products or their combinati...
ABSTRACT:
The present invention relates to a process for preparation of stable crystalline Form (designated as –SBU) of Busulfan (I)
Novel crystalline Form-SBU of Busulfan is characterized by X-ray powder diffraction pattern comprising 2?° peaks selected from the XRPD peak set of 12.48, 14.18, 15.24, 16.21, 18....
The present invention relates to a film coating tablet comprising Olaparib or a pharmaceutically acceptable salt thereof, wherein the film coating tablet is obtained by Rapid mixture granulator.
The present invention further relates to a process for manufacturing a film coating tablet of the invention as well as ...
The present invention provides to an improved process for the preparation of thermodynamically stable crystalline Lenvatinib mesylate of formula (I).
The present invention also provides novel crystalline Lenvatinib mesylate (I) designated as form SL obtained by the improved process of present invention is h...
The present invention provides to an improved process for the preparation of highly pure crystalline Pazopanib Hydrochloride of formula (I).
(I)
The crystalline Pazopanib Hydrochloride (I) obtained by improved process of the present invention is having purity of greater than 99.9% (Area % by HPLC).
Pazopani...
The invention relates to a pharmaceutical composition of crystalline Form B of Palbociclib having particle size less than 30µm (D90) comprising a process of wet granulation, wherein the composition optionally consisting organic acid and exhibiting in vitro drug release of more than 90% of active released within 30...
ABSTRACT
Process for the Preparation of Palbociclib
The present invention provides to an improved process for the preparation of highly pure crystalline Palbociclib of formula (I)
The crystalline Palbociclib (I) obtained by improved process of the present invention is having purity of greater than 99.8% (% w/w by...
The invention relates to a unique and stable pharmaceutical composition derived from wet granulation process wherein said composition exhibiting cumulative in vitro release profile ranging from >60% of Erlotinib HCl is released within 10 minutes, >70% of Erlotinib HCl is released within 15 minutes and >85% of Erl...
ORAL DISPERSIBLE FILM OF NIFEDIPINE
The present invention discloses composition of an oral dispersible film of Nifedipine comprising film forming agent, plasticizer, saliva stimulating agent, sweetener, solvent and a flavouring agent. The invention further discloses process of preparing of oral dispersible fi...
The present invention discloses the novel orodispersible film composition of Carbamazepine comprising film forming agent, plasticizer, saliva stimulating agent, sweetening agent, solvent and a flavouring agent.
The invention further discloses process of preparing of orodispersible film of Carbamazepine.
The ...
The present invention provides a commercially viable one pot process for the preparation of pure Methyl 2-(2-methylphenoxymethyl) phenylglyoxylate of formula (I).
which is useful intermediate for preparing Kresoxim-methyl.
The present invention also provides a process for the purification of Methyl 2-(2-methylp...
Registered Trademarks
[Class : 35] Advertising Business Administration, Business Management Activities Including Distribution, Marketing Services Relating
[Class : 35] Business Administration, Business Functions, Business Management, Advertisement, Marketing, Trading, Promotion, Wholesaler, Importer, Exproter, Retailers, Distributors, Stockist Of Pharmaceuticals, Medicinal, Ayurvedic Preparation, Skincare, Dermatology And Cosmetics Products And Healthcare Goods, Business Research, Business Investigations, Business Appraisals, ...
[Class : 35] Business Administration, Business Functions, Business Management, Advertisement, Marketing, Trading, Promotion, Wholesaler, Importer, Exproter, Retailers, Distributors, Stockist Of Pharmaceuticals, Medicinal, Ayurvedic Preparation, Skincare, Dermatology And Cosmetics Products And Healthcare Goods, Business Research, Business Investigations, Business Appraisals, ...
View +4 more Brands for Shivalik Rasayan Limited.
Charges
25 November 2015
Indusind Bank Ltd.
15 Crore
18 April 1980
The Pradeshiya Industrtial & Investment Corporation Up Ltd
40 Lak
10 May 1985
Industrial Finance Corporation Of India
9 Lak
15 November 1984
Industrial Finance Corporation Of India
15 Lak
15 November 1984
Industrial Finance Corporation Of India
28 Lak
06 May 1987
Industrial Finance Corporation Of India
10 Lak
23 February 1987
Industrial Finance Corporation Of India
3 Lak
28 February 1984
Punjab National Bank
48 Lak
21 April 2020
Citi Bank N.a.
5 Crore
21 April 2020
Citi Bank N.a.
15 Crore
29 September 2023
Idbi Bank Limited
0
31 March 2023
Citi Bank N.a.
0
27 January 2023
Others
0
13 October 2022
Idbi Bank Limited
0
13 April 2022
Others
0
21 April 2020
Citi Bank N.a.
0
21 April 2020
Citi Bank N.a.
0
25 November 2015
Others
0
15 November 1984
Industrial Finance Corporation Of India
0
15 November 1984
Industrial Finance Corporation Of India
0
18 April 1980
The Pradeshiya Industrtial & Investment Corporation Up Ltd
0
10 May 1985
Industrial Finance Corporation Of India
0
23 February 1987
Industrial Finance Corporation Of India
0
06 May 1987
Industrial Finance Corporation Of India
0
28 February 1984
Punjab National Bank
0
29 September 2023
Idbi Bank Limited
0
31 March 2023
Citi Bank N.a.
0
27 January 2023
Others
0
13 October 2022
Idbi Bank Limited
0
13 April 2022
Others
0
21 April 2020
Citi Bank N.a.
0
21 April 2020
Citi Bank N.a.
0
25 November 2015
Others
0
15 November 1984
Industrial Finance Corporation Of India
0
15 November 1984
Industrial Finance Corporation Of India
0
18 April 1980
The Pradeshiya Industrtial & Investment Corporation Up Ltd
0
10 May 1985
Industrial Finance Corporation Of India
0
23 February 1987
Industrial Finance Corporation Of India
0
06 May 1987
Industrial Finance Corporation Of India
0
28 February 1984
Punjab National Bank
0
29 December 2023
Others
0
29 September 2023
Idbi Bank Limited
0
31 March 2023
Citi Bank N.a.
0
27 January 2023
Others
0
13 October 2022
Idbi Bank Limited
0
13 April 2022
Others
0
21 April 2020
Citi Bank N.a.
0
15 November 1984
Industrial Finance Corporation Of India
0
21 April 2020
Citi Bank N.a.
0
25 November 2015
Others
0
15 November 1984
Industrial Finance Corporation Of India
0
18 April 1980
The Pradeshiya Industrtial & Investment Corporation Up Ltd
0
10 May 1985
Industrial Finance Corporation Of India
0
23 February 1987
Industrial Finance Corporation Of India
0
28 February 1984
Punjab National Bank
0
06 May 1987
Industrial Finance Corporation Of India
0
Documents
Optional Attachment-(1)-19112020
List of share holders, debenture holders;-19112020
Optional Attachment-(3)-19112020
Copy of MGT-8-19112020
Form MGT-7-19112020_signed
Form MGT-7-17112020_signed
Optional Attachment-(3)-13112020
List of share holders, debenture holders;-13112020
Copy of MGT-8-13112020
Optional Attachment-(1)-13112020
Form MGT-15-06102020_signed
Form CHG-1-03102020_signed
Form CHG-1-01102020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20200930
Form DPT-3-30092020-signed
Optional Attachment-(1)-30092020
Instrument(s) of creation or modification of charge;-30092020
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20200930
Form CHG-4-06072020_signed
Letter of the charge holder stating that the amount has been satisfied-06072020
CERTIFICATE OF SATISFACTION OF CHARGE-20200706
Instrument(s) of creation or modification of charge;-18062020
Optional Attachment-(1)-18062020
Form CHG-1-18062020_signed
CERTIFICATE OF REGISTRATION OF CHARGE-20200618
XBRL document in respect Consolidated financial statement-17122019
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-17122019
Form AOC-4(XBRL)-17122019_signed
Optional Attachment-(1)-05112019
Form MGT-7-05112019_signed
